Predictors of elevated intraocular pressure after intravitreal injection of anti-vascular endothelial growth factors: a prospective observational study
Keywords:
Glaucoma, Intraocular pressure, intravitreal injections, Bevacizumab, RetinaAbstract
Purpose: To investigate the patterns and predictors of intraocular pressure (IOP) changes after intravitreal injection (IVI) of anti-vascular endothelial growth factors (anti-VEGFs).
Methods: This study enrolled 32 men and 16 women (mean age, 65.3±12.3 years) who underwent IVI of anti-VEGFs between January and March 2020 in our department. IOPs were measured using Goldmann applanation tonometry. Potential predictors included age, sex, lens status, axial length, history of glaucoma, number of previous IVIs, diagnosis, and post-injection vitreous reflux.
Results: The respective mean IOP was 16.2 mmHg, 32.7 mmHg, 21.7 mmHg, and 18.3 mmHg at baseline and at 5, 15, and 30 minutes after IVI. IOP elevation of ≥15 mmHg was observed in 48% of eyes at 5 minutes after IVI; all spikes resolved and the IOP reduced to <21 mmHg within 60 minutes. Previous IVI number (r=0.346, p=0.016) and baseline IOP (r=0.304, p=0.04) were associated with IOP at 5 minutes after IVI. Baseline IOP was associated with IOPs at 15 and 30 minutes after IVI (r=0.488-0.573, p<0.001). In multivariate regression analysis, the previous IVI number (b=0.55, p=0.04) was an independent predictor of IOP at 5 minutes after IVI.
Conclusion: Transient but substantial IOP elevation shortly after IVI of anti-VEGFs was positively correlated with the number of previous IVIs; this could be used to stratify patients for IOP spike prophylaxis, especially those with advanced glaucoma at risk of further optic nerve damage secondary to acute ocular hypertension. Ophthalmologists should assess patient susceptibility to glaucomatous damage, along with the risks and
complications of prophylaxis
References
Kim LN, Mehta H, Barthelmes D, Nguyen V, Gillies MC. Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration. Retina 2016;36:1418-31.
Ho M, Lo EC, Young AL, Liu DT. Outcome of polypoidal choroidal vasculopathy at 1 year by combined therapy of photodynamic therapy with ranibizumab and predictive factors governing the outcome. Eye (Lond) 2014;28:1469-76.
Bahrami B, Hong T, Gilles MC, Chang A. Anti-VEGF therapy for diabetic eye diseases. Asia Pac J Ophthalmol (Phila) 2017;6:535-45.
Jiang Y, Mieler WF. Update on the use of anti-VEGF intravitreal therapies for retinal vein occlusions. Asia Pac J Ophthalmol (Phila) 2017;6:546-53.
Jeong S, Sagong M, Chang W. Acute angle closure attack after an intravitreal bevacizumab injection for branch retinal vein occlusion: a case report. BMC Ophthalmol 2017;17:25.
Mansour AM, Bynoe LA, Welch JC, et al. Retinal vascular events after intravitreal bevacizumab. Acta Ophthalmol 2010;88:730-5.
Quigley HA, Anderson DR. Distribution of axonal transport blockade by acute intraocular pressure elevation in the primate optic nerve head. Invest Ophthalmol Vis Sci 1977;16:640-4.
Quigley H, Anderson DR. The dynamics and location of axonal transport blockade by acute intraocular pressure elevation in primate optic nerve. Invest Ophthalmol 1976;15:606-16.
Yannuzzi NA, Patel SN, Bhavsar KV, Sugiguchi F, Freund KB. Predictors of sustained intraocular pressure elevation in eyes receiving intravitreal anti-vascular endothelial growth factor therapy. Am J Ophthalmol 2014;158:319-27.e2.
Lee JW, Park H, Choi JH, et al. Short-term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab. BMC Ophthalmol 2016;16:69.
Farhood QK, Twfeeq SM. Short-term intraocular pressure changes after intravitreal injection of bevacizumab in diabetic retinopathy patients. Clin Ophthalmol 2014;8:599-604.
Hollands H, Wong J, Bruen R, Campbell RJ, Sharma S, Gale J. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 2007;42:807-11.
Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol 2008;146:930-4.e1.
Park J, Lee M. Short-term effects and safety of an acute increase of intraocular pressure after intravitreal bevacizumab injection on corneal endothelial cells. BMC Ophthalmol 2018;18:17.
Yan DB, Coloma FM, Metheetrairut A, Trope GE, Heathcote JG, Ethier CR. Deformation of the lamina cribrosa by elevated intraocular pressure. Br J Ophthalmol 1994;78:643-8.
Michelson G, Groh MJ, Langhans M. Perfusion of the juxtapapillary retina and optic nerve head in acute ocular hypertension. Ger J Ophthalmol 1996;5:315-21.
Anderson DR, Davis EB. Sensitivities of ocular tissues to acute pressure-induced ischemia. Arch Ophthalmol 1975;93:267-74.
Tsai YY, Lin JM. Effect of laser-assisted in situ keratomileusis on the retinal nerve fiber layer. Retina 2000;20:342-5.
Kolker AE. Visual prognosis in advanced glaucoma: a comparison of medical and surgical therapy for retention of vision in 101 eyes with advanced glaucoma. Trans Am Ophthalmol Soc 1977;75:539-55.
Savage JA, Thomas JV, Belcher CD 3rd, Simmons RJ. Extracapsular cataract extraction and posterior chamber intraocular lens implantation in glaucomatous eyes. Ophthalmology 1985;92:1506-16.
Tranos P, Bhar G, Little B. Postoperative intraocular pressure spikes: the need to treat. Eye (Lond) 2004;18:673-9.
Menke MN, Salam A, Framme C, Wolf S. Long-term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with ranibizumab. Ophthalmologica 2013;229:168-72.
Baek SU, Park IW, Suh W. Long-term intraocular pressure changes after intravitreal injection of bevacizumab. Cutan Ocul Toxicol 2016;35:310-4.
Hoang QV, Mendonca LS, Della Torre KE, Jung JJ, Tsuang AJ, Freund KB. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology 2012;119:321-6.
Agard E, Elchehab H, Ract-Madoux G, Russo A, Lagenaite C, Dot C. Repeated intravitreal anti-vascular endothelial growth factor injections can induce iatrogenic ocular hypertension, especially in patients with open-angle glaucoma. Can J Ophthalmol 2015;50:127-31.
Beato J, Pedrosa AC, Pinheiro-Costa J, et al. Long-term effect of anti-VEGF agents on intraocular pressure in age-related macular degeneration. Ophthalmic Res 2016;56:30-4.
Pershing S, Bakri SJ, Moshfeghi DM. Ocular hypertension and intraocular pressure asymmetry after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmic Surg Lasers Imaging Retina 2013;44:460-4.
Hoang QV, Tsuang AJ, Gelman R, et al. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy. Retina 2013;33:179-87.
Eadie BD, Etminan M, Carleton BC, Maberley DA, Mikelberg FS. Association of repeated intravitreous bevacizumab injections with risk for glaucoma surgery. JAMA Ophthalmol 2017;135:363-8.
Liu L, Ammar DA, Ross LA, Mandava N, Kahook MY, Carpenter JF. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Invest Ophthalmol Vis Sci 2011;52:1023-34.
Bracha P, Moore NA, Ciulla TA, WuDunn D, Cantor LB. The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: a review. Surv Ophthalmol 2018;63:281-95.
Murray CD, Wood D, Allgar V, Walters G, Gale RP. Short-term intraocular pressure trends following intravitreal ranibizumab injections for neovascular age-related macular degeneration-the role of oral acetazolamide in protecting glaucoma patients. Eye (Lond) 2014;28:1218-22.
El Chehab H, Le Corre A, Agard E, Ract-Madoux G, Coste O, Dot C. Effect of topical pressure-lowering medication on prevention of intraocular pressure spikes after intravitreal injection. Eur J Ophthalmol 2013;23:277-83.
Knip MM, Valimaki J. Effects of pegaptanib injections on intraocular pressure with and without anterior chamber paracentesis: a prospective study. Acta Ophthalmol 2012;90:254-8.
Helbig H, Noske W, Kleineidam M, Kellner U, Foerster MH. Bacterial endophthalmitis after anterior chamber paracentesis. Br J Ophthalmol 1995;79:866.
Azuara-Blanco A, Katz LJ. Infectious keratitis in a paracentesis tract. Ophthalmic Surg Lasers 1997;28:332-3.
Trivedi D, Denniston AK, Murray PI. Safety profile of anterior chamber paracentesis performed at the slit lamp. Clin Exp Ophthalmol 2011;39:725-8.
Aref AA. Management of immediate and sustained intraocular pressure rise associated with intravitreal antivascular endothelial growth factor injection therapy. Curr Opin Ophthalmol 2012;23:105-10.
Peters S, Heiduschka P, Julien S, et al. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 2007;143:995-1002.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Hong Kong Journal of Ophthalmology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The Journal has a fully Open Access policy and publishes all articles under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) licence. For any use other than that permitted by this license, written permission must be obtained from the Journal.
